Attacking malignant cells that survive therapy: Exploiting immunogenic modulation

Oncoimmunology. 2013 Dec 1;2(12):e26937. doi: 10.4161/onci.26937. Epub 2013 Nov 6.

Abstract

We have recently defined "immunogenic modulation," a mechanism whereby malignant cells that survive anticancer therapy, due to sublethal delivery or development of treatment resistance, become nonetheless more sensitive to killing by cytotoxic T lymphocytes. This mechanism can be exploited to identify which therapies will best synergize with immunotherapy, potentially maximizing patient clinical benefit.

Keywords: CTL-mediated lysis; antigen-processing machinery; calreticulin; immunogenic modulation; immunotherapy; therapeutic cancer vaccine.